anti-MOK Protein Kinase (MOK) Antibodies

Human MOK Protein Kinase (MOK) interaction partners

1. our results suggest MOK promoter hypomethylation is a common event and contributes to MOK overexpression in acute myeloid leukemia (show BCL11A Antibodies)

2. The findings indicate a statistically significant association of p.Gly82Ser polymorphism in RAGE (show AGER Antibodies) with DR in T2DM patients.

3. the expressions of ICK/MAK (show MAK Antibodies)/MOK proteins in the intestinal tract can be differentially and dynamically regulated, implicating a significant functional diversity within this group of protein kinases.

4. Our results suggest that RAGE (show AGER Antibodies) may be important in tumor invasion and could be a potential predictor for the prognosis of hepatocellular carcinoma patients.

5. PBMNC from type 2 diabetics were more sensitive to innate immune stimulation with LPS (show IRF6 Antibodies) and monoclonal agonist anti-TLR4 (show TLR4 Antibodies) than were cells from ND. The actions of LPS (show IRF6 Antibodies), anti-TLR4 (show TLR4 Antibodies) and anti-RAGE (show AGER Antibodies) potentiated the production of IL-6 (show IL6 Antibodies) and TNF-alpha (show TNF Antibodies) in both groups.

6. The RAGE (show AGER Antibodies) pathway may play an important role in STAT3 (show STAT3 Antibodies) induction in glioma-associated macrophages and microglia, a process that may be mediated through S100B (show S100B Antibodies).

7. RAGE (show AGER Antibodies) was demonstrated in all 8 yolk sac (show ADCY10 Antibodies) tumors and 21 of 26 embryonal carcinomas. In yolk sac (show ADCY10 Antibodies) tumors, RAGE (show AGER Antibodies) reactivity was diffusely present throughout the tumors. In embryonal carcinomas, RAGE (show AGER Antibodies) was identified only in yolk sac (show ADCY10 Antibodies) components

8. identification of MOK, a member of the mitogen-activated protein kinase (show MAPK1 Antibodies) superfamily, as one of the genes induced by a caudal (show CAD Antibodies)-related homeobox (show Lbx1 Antibodies) transcription factor, Cdx2 (show CDX2 Antibodies)

9. May provide suitable targets for immunotherapy of renal cell carcinoma.

10. Compared RAGE (show AGER Antibodies) and PAX-2 (show PAX2 Antibodies) staining in metastatic clear renal cell carcinoma.

Mouse (Murine) MOK Protein Kinase (MOK) interaction partners

1. the expressions of ICK/MAK (show MAK Antibodies)/MOK proteins in the intestinal tract can be differentially and dynamically regulated, implicating a significant functional diversity within this group of protein kinases.

2. identification of MOK, a member of the mitogen-activated protein kinase (show MAPK1 Antibodies) superfamily, as one of the genes induced by a caudal (show CAD Antibodies)-related homeobox (show PRRX1 Antibodies) transcription factor, Cdx2 (show CDX2 Antibodies)

3. RAGE (show AGER Antibodies) inactivation inhibits the atherosclerosis through reducing oxLDL-induced pro-inflammatory responses and oxidative stress in hyperlipidaemia.

4. Suppression of Egr-1 (show EGR1 Antibodies) may contribute to the protective mechanisms underlying the beneficial impact of RAGE (show AGER Antibodies) blockade or deletion in hepatic ischemia/reperfusion injury.